Targeted Antenatal Screening for Predicting Postpartum Thyroiditis and Its Evolution Into Permanent Hypothyroidism.


Journal

Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782

Informations de publication

Date de publication:
2020
Historique:
received: 04 02 2020
accepted: 27 03 2020
entrez: 5 5 2020
pubmed: 5 5 2020
medline: 29 5 2021
Statut: epublish

Résumé

Postpartum thyroiditis (PPT) has a prevalence of 1-22%, with an ~50% rate of evolution into permanent hypothyroidism (PH). PPT risk is assessed by measuring serum thyroid antibodies during gestation, as 1/3-1/2 of Ab+ve pregnant women will develop PPT. Family and personal history positive for autoimmune non-thyroid diseases (AINTDT), and consumption of swordfish increases while consumption of small oily fish decreases the risk of PPT. Monitoring thyroid function in a very high-risk subgroup avoids the costs of the Ab-based universal screening. We aimed at identifying such subgroup in 412 women followed from week 7-11 of gestation to month 12 postpartum. At study entry, we measured serum TPOAb, TgAb, TSH, FT4, FT3, and evaluated seafood consumption, familial history for thyroid diseases and AINTD, and personal history for AINTD. We measured TSH, FT4, FT3 at 1.5, 3, 6, and 12 months postpartum. PPT occurred in 63 women (15.3%), and PH in 34/63 (54%). Based on positivity/negativity for the three histories, women were classified into 8 categories, with PPT rates of 3.8-100%. Seafood consumption allowed further separation of subgroups having different PPT risks. We considered 11 possible strategies, termed [a] through [k]. Strategy [a] consisted in omitting gestational screening, while performing universal postpartum monitoring with TSH and one thyroid hormone; strategy [k] consisted in selective gestational screening with TPOAb and TgAb, based on history and fish consumption, and selective postpartum monitoring in TPOAb and/or TgAb+ve women. The 100% sensitivity, specificity and diagnostic accuracy of strategy [a] were counterbalanced by the highest costs (Euro 32,960 or 523 per each PPT caught). The corresponding numbers for strategy [k] were 78, 95, 93%, and Euro 8,920 or 182/PPT caught. These savings stem from gestational screening being done in 186 women, and postpartum monitoring done in 65/186 women. One gestational screning-free strategy was the cheapest (Euro 2,080 or 83/PPT caught), because based on postpartum monitoring of only 26 women, but had the lowest sensitivity (40%). Identification of pregnant women having different risks for PPT is feasible, with the costless evaluation of history and seafood consumption driving gestational screening of thyroid antibody status and postpartum monitoring of thyroid function.

Identifiants

pubmed: 32362873
doi: 10.3389/fendo.2020.00220
pmc: PMC7180182
doi:

Substances chimiques

Autoantibodies 0
Biomarkers 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

220

Informations de copyright

Copyright © 2020 Benvenga.

Références

J Endocrinol Invest. 2008 Dec;31(12):1063-8
pubmed: 19246971
Endocrine. 2016 Apr;52(1):120-9
pubmed: 26306774
Thyroid. 2006 Jun;16(6):573-82
pubmed: 16839259
J Clin Transl Endocrinol. 2018 Nov 23;15:12-18
pubmed: 30555788
Thyroid. 2016 Feb;26(2):296-305
pubmed: 26586553
Thyroid. 2011 Oct;21(10):1081-125
pubmed: 21787128
J Clin Endocrinol Metab. 2012 Feb;97(2):334-42
pubmed: 22312089
Endocrine. 2019 Jul;65(1):94-101
pubmed: 30840228
Thyroid. 2017 Mar;27(3):315-389
pubmed: 28056690
Br Med J (Clin Res Ed). 1988 Jan 23;296(6617):241-4
pubmed: 3124900

Auteurs

Salvatore Benvenga (S)

Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Master Program on Childhood, Adolescent and Women's Endocrine Health, University of Messina, Messina, Italy.
Interdepartmental Program on Molecular and Clinical Endocrinology, and Women's Endocrine Health, University Hospital, A.O.U. Policlinico G. Martino, Messina, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH